Study of teplizumab vs. no treatment in stage 2 type 1 diabetes
Treatments studied
Part of Hormones & metabolism, Immune system & allergy clinical trials.
This study watches people with stage 2 type 1 diabetes who either get teplizumab or not, to compare their real-world experiences. It helps researchers learn how the drug affects daily life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage 2 type 1 diabetes (confirmed by autoantibodies and abnormal blood sugar).
- You have not yet been diagnosed with stage 3 type 1 diabetes, or it happened in the last 18 months.
- You are 8 years old or older.
- You get medical care in the United States.
- You can fill out a survey at the start.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two different medications (Anti-Thymocyte Globulin and Adalimumab or Verapamil) to see if they can slow down the loss of insulin production in people with newly diagnosed type 1 diabetes. Participants will be randomly assigned to receive one of the treatments and will be followed for about a year to see how well their bodies still make insulin.
This study looks at real-world outcomes in patients with type 1 diabetes who received teplizumab through managed access programs. It helps researchers understand how well the treatment works outside of a clinical trial setting.
This study follows people who have already received teplizumab (a treatment to delay type 1 diabetes) to see how they do over time. It aims to understand the long-term effects in routine care.
This study tracks people with stage 2 type 1 diabetes to see how they do over time, either with or without treatment with a drug called TZIELD. It helps doctors learn more about the disease and the effects of this treatment.
This trial tests a new way to give a medicine called anti-thymocyte globulin (ATG) with or without verapamil, a blood pressure drug. It aims to slow down the loss of insulin-making cells in people newly diagnosed with type 1 diabetes.
This study tests whether a GLP-1 receptor agonist (a type of medicine that helps control blood sugar and appetite) can improve metabolic health in people with early type 1 diabetes. It may be an option if you have already taken teplizumab to delay the disease or were recently diagnosed with type 1 diabetes.
Hear when a new Type 1 diabetes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.